Arch Therapeutics Co-Founder Dr. Ellis-Behnke to Speak at Nanomanufacturing Summit 2013 in Philadelphia, October 15, 2013
10 oct. 2013 09h00 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Oct 10, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), is pleased to announce that co-founding and inventing scientist, Dr. Rutledge...
Arch Therapeutics Announces Approval of $1 Million Massachusetts Life Sciences Center Accelerator Loan
07 oct. 2013 09h00 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Oct 7, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27
20 sept. 2013 09h00 HE
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Sep 20, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the Boulder Peptide...
Arch Therapeutics Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
03 sept. 2013 09h00 HE
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Sep 3, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the 15th Annual Rodman...
Arch Therapeutics Announces Plans for Upcoming Activities
06 août 2013 15h05 HE
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Aug 6, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Reports on Current Activities
30 juil. 2013 09h00 HE
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 30, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Co-Founder Dr. Ellis-Behnke Speaks at 6th Annual CLINAM Nanomedicine Summit in Basel, Switzerland
23 juil. 2013 09h50 HE
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 23, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu, Greece
16 juil. 2013 09h00 HE
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 16, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Appoints Senior Management Team Members
08 juil. 2013 09h00 HE
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 8, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Introduces Experienced Directors and Executive Leadership
02 juil. 2013 09h00 HE
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 2, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...